Faruqi & Faruqi Issues Reminder to Baxter Investors — Lead Plaintiff Deadline December 15, 2025

Faruqi & Faruqi, LLP, a US-based national securities‑litigation firm, issued a notice on November 30, 2025, urging investors in Baxter International, Inc. (NYSE: BAX) to consider serving as lead plaintiff in a pending class‑action lawsuit. The deadline to file for lead‑plaintiff status is December 15, 2025. The lawsuit alleges that Baxter and its executives violated federal securities laws by making false or misleading statements — or omitting material information — about the safety and reliability of their medical device, the Novum LVP infusion pump. According to the complaint: (a) the Novum LVP suffered systemic defects causing underinfusion, overinfusion, or total failure to deliver fluids; (b) Baxter was aware of multiple malfunctions, related injuries and even deaths; (c) Baxter’s customer alerts did not sufficiently address the underlying design flaws; (d) there was a serious risk that customers would need to stop using existing devices and new sales would be halted; and (e) Baxter’s prior public statements about the product’s safety, effectiveness, rollout, customer feedback, and sales prospects were materially false and misleading. The full extent of the alleged misconduct came to light on July 31, 2025, when Baxter publicly announced a voluntary temporary pause on shipments and installations of the Novum LVP, and said it could not commit to a resumption date. On that news, Baxter’s stock price plunged 22.4%. Investors who purchased Baxter securities between February 23, 2022 and July 30, 2025 are encouraged to contact Faruqi & Faruqi (via partner James (Josh) Wilson) to discuss legal options. Participation does not require serving as lead plaintiff — but doing so may give a stronger voice in directing the litigation. The firm also welcomes tips from whistleblowers, former employees, shareholders or others who may have information related to Baxter’s conduct. #Baxter #ClassAction #NovumLVP #InvestorAlert #SlimScan #GrowthStocks #CANSLIM